SCHEMBL6797974

SCHEMBL6797974

COc1cc(-c2ccccc2)nn1CCOc1ccc2cc(Br)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
KMT2A Q03164 3/20 0.40
PPARG P37231 2/20 0.39
PPARA Q07869 2/20 0.39
MAPT P10636 3/20 0.38
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
FPR1 P21462 1/20 0.37
FPR2 P25090 1/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
RXFP1 Q9HBX9 2/20 0.36
GAA P10253 2/20 0.36
GALR3 O60755 1/20 0.36
NPY1R P25929 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6607212 0.90 MAPT (0.43) RAB9ANPC1KMT2APPARGPPARA
SCHEMBL6602434 0.88 PPARG (0.39) RAB9ANPC1KMT2APPARGPPARA
SCHEMBL6602671 0.84 RXFP1 (0.39) RAB9ANPC1KMT2AMAPTLMNA
SCHEMBL6602248 0.82 NPC1 (0.51) RAB9ANPC1KMT2APPARGMEN1
SCHEMBL6603505 0.81 IKBKB (0.41) RAB9ANPC1KMT2AMAPTMEN1
SCHEMBL6603315 0.81 TTK (0.35) RAB9ANPC1KMT2APPARGPPARA
SCHEMBL6606028 0.76 MGAM (0.43) RAB9ANPC1KMT2ALMNASMN1; SMN2
SCHEMBL6803979 0.76 MAPT (0.37) KMT2AMAPTLMNASMN1; SMN2MEN1
SCHEMBL6602524 0.75 ADORA1 (0.40) RAB9ANPC1KMT2AMAPTLMNA
SCHEMBL6602662 0.75 PPARG (0.42) RAB9ANPC1KMT2APPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 RAB9A 2533/4885NPC1 2642/4885KMT2A 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.